纤维蛋白原/前白蛋白比值预测消化系统肿瘤预后的研究进展

doi:10.3760/cma.j.cn371439-20250612-00017

国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (2): 111-114.doi: 10.3760/cma.j.cn371439-20250612-00017

纤维蛋白原/前白蛋白比值预测消化系统肿瘤预后的研究进展

杨睿, 郭信伟(), 刘阳晨

扬州大学附属泰兴人民医院肿瘤放疗科，泰兴 225400

收稿日期:2025-06-12 出版日期:2026-02-08 发布日期:2026-01-29
通讯作者: 郭信伟，Email：guoxinwei66688@163.com
基金资助:
泰州市社会发展项目(SSF20230012);江苏卫生健康职业学院校级科研项目(JKCY202420)

Research progress on the impact of fibrinogen/prealbumin ratio for the prediction of prognosis of digestive system tumors

Yang Rui, Guo Xinwei(), Liu Yangchen

Department of Radiation Oncology， Taixing People's Hospital Affiliated to Yangzhou University， Taixing 225400， China

Received:2025-06-12 Online:2026-02-08 Published:2026-01-29
Contact: Guo Xinwei， Email：guoxinwei66688@163.com
Supported by:
Taizhou Social Development Project(SSF20230012);School-level Scientific Research Project of Jiangsu Health Vocational College(JKCY202420)

摘要/Abstract

摘要：

消化系统肿瘤已成为全球范围内的主要健康问题，其预后预测一直是临床研究的热点。纤维蛋白原/前白蛋白比值（FPR）作为一种新型的炎症和营养状态生物标志物，近年来在消化系统肿瘤的预后预测中展现出重要的临床价值，未来研究可着重于FPR与其他炎症、营养指标的结合应用，进一步提高消化系统肿瘤患者预后预测的准确性。

关键词: 纤维蛋白原, 前白蛋白, 消化系统肿瘤, 预后, 纤维蛋白原/前白蛋白比值

Abstract:

Digestive system tumors have become a major global health concern， and prognosis prediction remains a focus of clinical research. The fibrinogen to prealbumin ratio （FPR）， as a novel biomarker reflecting inflammatory and nutritional status， has demonstrated significant clinical value in the prognosis prediction of digestive system tumors in recent years. Future research can focus on the combined application of FPR with other inflammatory and nutritional indicators to further improve the accuracy of prognosis prediction for patients with digestive system tumors.

Key words: Fibrinogen, Prealbumin, Digestive system neoplasms, Prognosis, Fibrinogen to prealbumin ratio

杨睿, 郭信伟, 刘阳晨. 纤维蛋白原/前白蛋白比值预测消化系统肿瘤预后的研究进展[J]. 国际肿瘤学杂志, 2026, 53(2): 111-114.

Yang Rui, Guo Xinwei, Liu Yangchen. Research progress on the impact of fibrinogen/prealbumin ratio for the prediction of prognosis of digestive system tumors[J]. Journal of International Oncology, 2026, 53(2): 111-114.

参考文献 29

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708.
[2]	江山, 徐阳涛, 刘昕, 等. 基线外周血炎性标志物对免疫治疗联合靶向治疗中晚期肝细胞癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2023, 50(10): 600-607. DOI: 10.3760/cma.j.cn371439-20230704-00114.
[3]	Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1): 263. DOI: 10.1038/s41392-021-00658-5.
[4]	Liu X, Shi B. Progress in research on the role of fibrinogen in lung cancer[J]. Open Life Sci, 2020, 15(1): 326-330. DOI: 10.1515/biol-2020-0035. pmid: 33817221
[5]	Tupikowski K, Jaobsche-Policht U, Bittner J, et al. The influences of selected clotting and fibrinolysis factors on survival of patients with kidney tumors—a prospective study[J]. Arch Med Sci, 2023, 19(4): 1003-1010. DOI: 10.5114/aoms/128845. pmid: 37560740
[6]	Zhang X, Zhao W, Chen X, et al. Combining the fibrinogen-to-pre-albumin ratio and prognostic nutritional index (FPR-PNI) predicts the survival in elderly gastric cancer patients after gastrectomy[J]. Onco Targets Ther, 2020, 13: 8845-8859. DOI: 10.2147/OTT.S264199.
[7]	Li B, Deng H, Zhou Z, et al. The prognostic value of the fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis[J]. Cancer Cell Int, 2022, 22(1): 22. DOI: 10.1186/s12935-022-02445-w.
[8]	Zhang L, Wang Z, Xiao J, et al. Prognostic value of fibrinogen-to-albumin ratio in patients with gastric cancer receiving first-line chemotherapy[J]. Oncol Lett, 2020, 20(4): 10. DOI: 10.3892/ol.2020.11871.
[9]	Deng S, Fan Z, Xia H, et al. Fibrinogen/albumin ratio as a promising marker for predicting survival in pancreatic neuroendocrine neoplasms[J]. Cancer Manag Res, 2021, 13: 107-115. DOI: 10.2147/CMAR.S275173. pmid: 33447083
[10]	Feng JF, Wang L, Jiang YH, et al. A novel prognostic index in patients with resectable esophageal squamous cell carcinoma: fibrinogen/prealbumin ratio[J]. Rev Invest Clin, 2020, 72(1): 46-54. DOI: 10.24875/RIC.19003184. pmid: 32132740
[11]	Li H, Sun Y, Wang C, et al. Prognostic value of fibrinogen to prealbumin ratio (FPR) in resectable gastric cancer[J]. J Inflamm Res, 2024, 17: 1325-1335. DOI: 10.2147/JIR.S440832. pmid: 38434582
[12]	Zhang J, Li SQ, Liao ZH, et al. Prognostic value of a novel FPR biomarker in patients with surgical stage Ⅱ and Ⅲ gastric cancer[J]. Oncotarget, 2017, 8(43): 75195-75205. DOI: 10.18632/oncotarget.20661 pmid: 29088857
[13]	Tang S, Lin L, Cheng J, et al. The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer[J]. BMC Cancer, 2020, 20(1): 382. DOI: 10.1186/s12885-020-06866-6.
[14]	Yan H, Liu T, Yu R, et al. The role of preoperative FPR and FAR in prognostic evaluation of stages Ⅱ and Ⅲ radical colorectal cancer: a single-center retrospective study[J]. Medicine (Baltimore), 2024, 103(20): e38145. DOI: 10.1097/MD.0000000000038145.
[15]	Ying HQ, Sun F, Liao YC, et al. The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211022886. DOI: 10.1177/17588359211022886.
[16]	Chen C, Liu Y, Han P, et al. Research progress of preoperative FPR, FAR or AFR in patients with colorectal cancer[J]. Cancer Manag Res, 2021, 13: 1791-1801. DOI: 10.2147/CMAR.S292605. pmid: 33654428
[17]	Yan H, Chen S, Qiong Y, et al. Preoperative prealbumin-to-fibrinogen ratio to predict survival outcomes in hepatocellular carcinoma patients after hepatic resection[J]. J Med Biochem, 2022, 41(3): 290-298. DOI: 10.5937/jomb0-32980. pmid: 36042905
[18]	Shen Y, Xu Y, Wei J, et al. The prognostic role of circulating FPR before operation in patients with BCLC A-C hepatocellular carcinoma: a retrospective cohort study[J]. J Hepatocell Carcinoma, 2022, 9: 467-476. DOI: 10.2147/JHC.S369168. pmid: 35669908
[19]	Li C, Fan Z, Guo W, et al. Fibrinogen-to-prealbumin ratio: a new prognostic marker of resectable pancreatic cancer[J]. Front Oncol, 2023, 13: 1149942. DOI: 10.3389/fonc.2023.1149942.
[20]	Chang S, Zou Y, Huang J, et al. Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection[J]. World J Surg Oncol, 2024, 22(1): 284. DOI: 10.1186/s12957-024-03524-0.
[21]	Gu Y, Hua Q, Li Z, et al. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer[J]. BMC Cancer, 2023, 23(1): 227. DOI: 10.1186/s12885-023-10653-4.
[22]	Zhang Y, Liu N, Liu C, et al. High fibrinogen and platelets correlate with poor survival in gastric cancer patients[J]. Ann Clin Lab Sci, 2020, 50(4): 457-462. pmid: 32826241
[23]	Milaniuk A, Drabko K, Chojęta A. Role of albumin and prealbumin in assessing nutritional status and predicting increased risk of infectious complications during childhood cancer treatment[J]. Acta Biochim Pol, 2024, 71: 13693. DOI: 10.3389/abp.2024.13693. pmid: 39619813
[24]	Wu X, Yu X, Chen C, et al. Fibrinogen and tumors[J]. Front Oncol, 2024, 14: 1393599. DOI: 10.3389/fonc.2024.1393599.
[25]	Zhang Y, Li Z, Zhang J, et al. Fibrinogen: a new player and target on the formation of pre-metastatic niche in tumor metastasis[J]. Crit Rev Oncol Hematol, 2025, 207: 104625. DOI: 10.1016/j.critrevonc.2025.104625.
[26]	Matsui R, Ida S, Ri M, et al. Impact of preoperative prealbumin levels on long-term prognosis in patients with gastric cancer after gastrectomy: a retrospective cohort study[J]. Gastric Cancer, 2024, 27(3): 611-621. DOI: 10.1007/s10120-024-01472-y.
[27]	Chiang HC, Lin MY, Lin FC, et al. Transferrin and prealbumin identify esophageal cancer patients with malnutrition and poor prognosis in patients with normal albuminemia: a cohort study[J]. Nutr Cancer, 2022, 74(10): 3546-3555. DOI: 10.1080/01635581.2022.2079687.
[28]	Nanashima A, Hiyoshi M, Imamura N, et al. Preoperative prognostic nutritional index is a significant predictive factor for posthepatectomy bile leakage[J]. Ann Hepatobiliary Pancreat Surg, 2021, 25(4): 477-484. DOI: 10.14701/ahbps.2021.25.4.477.
[29]	Liu B, Qian J, Zhou Y, et al. Prognostic assessment of colorectal cancer patients after laparoscopic surgery: a comprehensive evaluation of the Glasgow prognostic score and fibrinogen-to-prealbumin ratio[J]. Med Sci Monit, 2024, 30: e942658. DOI: 10.12659/MSM.942658.

纤维蛋白原/前白蛋白比值预测消化系统肿瘤预后的研究进展

Research progress on the impact of fibrinogen/prealbumin ratio for the prediction of prognosis of digestive system tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邱可欣, 李梦真, 国浩然, 凡梦思, 闫莉. 老年晚期卵巢癌患者不同手术方式的预后分析[J]. 国际肿瘤学杂志, 2025, 52(9): 576-582.
[2]	刘美, 胡玉崇, 李凤桐, 朝乐门, 柳檬, 亢琳琳. SHCBP1在恶性肿瘤中的作用机制及临床研究进展[J]. 国际肿瘤学杂志, 2025, 52(9): 583-586.
[3]	芦兵, 熊思玉, 蒋汶宏, 俞婷婷. 果糖二磷酸醛缩酶A在肺癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(4): 242-245.
[4]	杨胜军, 任江, 杨丹, 龙宇, 商群献. 非小细胞肺癌组织中miR-4262、NRG1的表达水平及临床意义[J]. 国际肿瘤学杂志, 2025, 52(3): 129-135.
[5]	王逸, 王强力, 张甲, 杨懿瑾, 王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[6]	韩涛, 贾沛沛, 鲁静. iRhom1、iRhom2、TNF-α水平对宫颈癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2025, 52(3): 158-162.
[7]	叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.
[8]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[9]	姬海涛, 王延峰, 刘永成, 郝楠. 基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[10]	依帕拉·伊力哈木, 马涛, 王岩, 高春洁, 刘静, 赵婷, 王蕾. 体质量指数与不同绝经状态及分子分型乳腺癌患者生存预后的关系[J]. 国际肿瘤学杂志, 2025, 52(12): 745-757.
[11]	刘萍萍, 王俊毅, 林志伟, 陈大朝. 胃癌术后腹膜转移患者预后的影响因素分析[J]. 国际肿瘤学杂志, 2025, 52(12): 764-769.
[12]	宋雪琴, 李明英. HOXC10在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(12): 787-790.
[13]	代玉娟, 陈羡英, 黄巍, 陈大朝. 成人胶质瘤早期死亡影响因素分析及风险预测模型构建[J]. 国际肿瘤学杂志, 2025, 52(10): 609-613.
[14]	来瑞鹤, 盛丹丹, 何健, 丁重阳, 耿羽智. ¹⁸F-FDG PET/CT代谢参数在小细胞肺癌中的预后价值[J]. 国际肿瘤学杂志, 2025, 52(10): 614-620.
[15]	余洋, 唐仕敏, 杨露, 李娜. pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 43-47.